Considerations for affinity capture in an AAV platform downstream process
On demand

Considerations for affinity capture in an AAV platform downstream process

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Considerations for affinity capture in an AAV platform downstream process

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

In the rapidly evolving field of gene therapy, adeno-associated viral (AAV) vectors have shown increasing therapeutic promise. In recent years, a variety of different AAV-based therapies using different serotypes have received regulatory approval, and hundreds more are in clinical trials. From discovery to the clinic, as the quest to produce new, high-quality AAV molecules intensifies, an efficient and scalable platform purification process for many AAV serotypes is advantageous for both drug developers and CDMOs.

This presentation explores the considerations when evaluating a platform affinity capture step for the purification of AAV vectors. Specificity, binding capacity, purity, yield, scalability and reusability are parameters that will be addressed. Data will be shared with the industry-leading POROSTM CaptureSelectTM AAV affinity resin, and some comparison data will be included.

Attend this webinar to learn more about

  • Elements of a typical AAV downstream process
  • Key considerations to platform the affinity capture step in an AAV purification process
  • Performance data, including comparison of dynamic binding capacity data for POROS CaptureSelect AAV and other purification resins for AAV
  • Resin reuse studies to support a reduced cost of goods

Poros CaptureSelect resins: Pharmaceutical Grade Reagent. For Manufacturing and Laboratory Use Only. Not for diagnostic use or direct administration in humans or animals.

Jett Appel
Jett Appel
Field Applications Scientist at Thermo Fisher Scientifc

Jett Appel has been a Purification Field Applications Scientist at Thermo Fisher Scientific since 2021, supporting purification development and scale-up for monoclonal antibodies, viral vectors, nucleic acids, and recombinant proteins.

Prior to joining Thermo Fisher, Jett worked at Avid Bioservices, a contract development manufacturing organization (CDMO) based in Orange County, CA. During his 5 years of working at Avid, Jett first worked in Process Development and eventually transitioned to a Sr. Engineer role in the Manufacturing Sciences & Technology (MSAT) team, where he supported purification development and technology transfers for monoclonal IgGs, IgMs, bispecific antibodies, scFvs, and recombinant enzymes up to 2000 L bioreactor scale.

Jett received a Bachelor’s degree in Chemical and Biomolecular Engineering from UCLA in 2016. While at UCLA, he was involved in epigenetics research at the Steve Jacobsen Lab, which included studying the pathways involved in RNA-directed DNA methylation in Arabidopsis thaliana.